Abstract library

147 results for "budget impact".
#1303 Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals
Introduction: Lanreotide depot (LAN) was recently approved by the FDA to treat mGEP-NETs to improve progression-free survival.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Authors: Ortendahl J, Pulgar S, Cox D, Bentley T, ...
#315 The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors
Introduction: Accurate assessment of the primary tumor site and the extent of the metastatic burden are crucial and can be challenging, however, it is essential to the choice of optimal patient-tailored management.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof. Andrea Frilling
#1407 Nutritional Status and Nutritional Risk in Patients with Neuroendocrine Tumors
Introduction: Malnutrition is common in patients with cancer and is associated with impaired function. No data are available on nutritional status (NS) and nutritional risk (NR) in patients with neuroendocrine tumors (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: PhD Gitte Dam
Authors: Borre M, Dam G, Knudsen A, Grønbæk H, ...
#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
Authors: Williams M, Reid K, Ng S, Benny A, ...
#365 FDOPA PET/CT has a Significant Clinical Impact on the Management of Patients with Neuroendocrine Tumors
Introduction: Studies suggest that positron emission tomography (PET) using the dopamine-synthesis tracer [18F]fluoro-dihydroxyphenylalanine (FDOPA) may improve the clinical management of patients with NET.
Conference:
Category: Basic
Presenting Author: Dr. Michael Sørensen
#706 Is There a Therapeutic Impact of Segmental Portal Hypertension on Advanced Pancreatic Neuroendocrine Tumors?
Introduction: Well-differenciated locally advanced Pancreatic Neuroendocrine Tumors (PNET) lead to significant local complications due to segmental portal hypertension (SPH).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Frédéric Dumont
#868 Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Claudia Bestani
#1361 Evaluation of the Therapeutic Approaches Impacting on the Survival of Patients with an Advanced Pancreatic Neuroendocrine Tumor
Introduction: The therapeutic approaches in metastatic pancreatic neuroendocrine tumors (pNET) are currently used as a palliative strategy to control symptoms and potentially improving patient survival.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Sebastian Krug
Keywords: pNET
#1580 The Impact of the Pathologic Differentiation (Well or Poorly) and the Degree of Ki-67 Index in Patients with Metastatic WHO Grade 3 GEP-NETs
Introduction: There is few data for the treatment-outcome with etoposide plus platinum between well differentiated and poorly differentiated metastatic grade 3 GEP-NEC.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Seung Kim
Authors: Kim S, Park Y, ...
Keywords: Ki67 index
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond